Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.44 -3.4%	$1.81	$1.29 ▼ $13.07	$55.98M	-0.07	905,179 shs	542,981 shs
CNTA Centessa Pharmaceuticals	$13.14 +0.5%	$12.73	$7.90 ▼ $19.09	$1.75B	1.53	658,782 shs	751,590 shs
PHVS Pharvaris	$16.53 -1.1%	$15.45	$11.51 ▼ $25.50	$874.29M	-2.85	73,934 shs	189,848 shs
SLRN Acelyrin	$2.27	$2.32	$1.85 ▼ $7.25	$229.17M	1.07	1.24 million shs	N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	-3.36%	-2.70%	-31.43%	-50.17%	-86.78%
CNTA Centessa Pharmaceuticals	+0.54%	+2.10%	-4.16%	-15.50%	+63.43%
PHVS Pharvaris	-1.14%	+3.38%	-10.55%	+3.96%	-14.79%
SLRN Acelyrin	0.00%	0.00%	-8.10%	-15.30%	-44.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMEA Biomea Fusion	2.8031 of 5 stars	3.5	0.0	3.4	3.3	1.3
CNTA Centessa Pharmaceuticals	3.4457 of 5 stars	4.5	1.0	3.2	3.3	0.6
PHVS Pharvaris	2.1437 of 5 stars	3.5	3.0	3.1	0.8	0.0
SLRN Acelyrin	3.5246 of 5 stars	3.2	4.0	3.2	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMEA Biomea Fusion	3.09	Buy	$22.60	1,469.44% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.89	112.24% Upside
PHVS Pharvaris	3.00	Buy	$40.67	146.02% Upside
SLRN Acelyrin	2.40	Hold	$9.60	322.91% Upside

Current Analyst Ratings Breakdown

Latest PHVS, CNTA, SLRN, and BMEA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	CNTA Centessa Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/15/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/14/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$28.00 ➝ $25.00
5/8/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$6.00
5/8/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
5/6/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/29/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$28.00
4/2/2025	BMEA Biomea Fusion	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$11.00 ➝ $3.00
3/31/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/31/2025	CNTA Centessa Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$38.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$4.74 per share	N/A
CNTA Centessa Pharmaceuticals	$15M	116.99	N/A	N/A	$2.42 per share	5.43
PHVS Pharvaris	N/A	N/A	N/A	N/A	$7.95 per share	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMEA Biomea Fusion	-$117.25M	-$3.55	N/A	N/A	N/A	N/A	-118.90%	-93.66%	7/30/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$151.09M	-$1.81	N/A	N/A	N/A	N/A	-52.13%	-38.01%	8/12/2025 (Estimated)
PHVS Pharvaris	-$109.18M	-$3.01	N/A	N/A	N/A	N/A	-38.52%	-36.69%	8/13/2025 (Estimated)
SLRN Acelyrin	-$381.64M	-$2.69	N/A	N/A	N/A	N/A	-44.12%	-39.02%	8/12/2025 (Estimated)

Latest PHVS, CNTA, SLRN, and BMEA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SLRN Acelyrin	-$0.95	-$0.55	+$0.40	-$0.55	N/A	N/A
5/13/2025	Q1 2025	PHVS Pharvaris	-$0.80	-$0.89	-$0.09	-$0.89	N/A	N/A
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A
5/5/2025	Q1 2025	BMEA Biomea Fusion	-$0.84	-$0.80	+$0.04	-$0.80	N/A	N/A
4/7/2025	Q4 2024	PHVS Pharvaris	-$0.74	-$0.68	+$0.06	-$0.68	N/A	N/A
3/31/2025	Q4 2024	BMEA Biomea Fusion	-$1.00	-$0.81	+$0.19	-$0.81	N/A	N/A
3/24/2025	Q4 2024	CNTA Centessa Pharmaceuticals	-$0.38	-$0.34	+$0.04	-$0.84	N/A	N/A
3/19/2025	Q4 2024	SLRN Acelyrin	-$0.86	-$0.79	+$0.07	-$0.79	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMEA Biomea Fusion	N/A	3.39	3.39
CNTA Centessa Pharmaceuticals	0.15	21.52	21.52
PHVS Pharvaris	N/A	19.08	19.08
SLRN Acelyrin	N/A	7.15	7.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMEA Biomea Fusion	96.72%
CNTA Centessa Pharmaceuticals	82.01%
PHVS Pharvaris	N/A
SLRN Acelyrin	87.31%

Insider Ownership

Company	Insider Ownership
BMEA Biomea Fusion	27.57%
CNTA Centessa Pharmaceuticals	7.09%
PHVS Pharvaris	11.84%
SLRN Acelyrin	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMEA Biomea Fusion	50	37.57 million	26.25 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.56 million	116.56 million	Optionable
PHVS Pharvaris	30	52.29 million	46.10 million	Not Optionable
SLRN Acelyrin	135	100.95 million	86.68 million	Optionable

PHVS, CNTA, SLRN, and BMEA Headlines

Recent News About These Companies

Millennium Management LLC Sells 772,770 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

May 25, 2025 | marketbeat.com

Reviewing Acelyrin (NASDAQ:SLRN) & Pulmatrix (NASDAQ:PULM)

May 21, 2025 | americanbankingnews.com

132,870 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Acquired by Stonepine Capital Management LLC

May 20, 2025 | marketbeat.com

Dimensional Fund Advisors LP Buys New Shares in Acelyrin, Inc. (NASDAQ:SLRN)

May 19, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Decreases Stake in Acelyrin, Inc. (NASDAQ:SLRN)

May 18, 2025 | marketbeat.com

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

May 13, 2025 | globenewswire.com

DAFNA Capital Management LLC Sells 514,905 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

May 10, 2025 | marketbeat.com

Acelyrin (SLRN) to Release Quarterly Earnings on Tuesday

May 8, 2025 | marketbeat.com

Alyeska Investment Group L.P. Buys Shares of 1,515,878 Acelyrin, Inc. (NASDAQ:SLRN)

May 8, 2025 | marketbeat.com

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

May 6, 2025 | globenewswire.com

Susquehanna Fundamental Investments LLC Takes $746,000 Position in Acelyrin, Inc. (NASDAQ:SLRN)

May 5, 2025 | marketbeat.com

Almitas Capital LLC Raises Stake in Acelyrin, Inc. (NASDAQ:SLRN)

May 4, 2025 | marketbeat.com

Acelyrin urges stockholders to vote for proposed merger with Alumis

May 2, 2025 | finance.yahoo.com

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

May 1, 2025 | globenewswire.com

Alumis and ACELYRIN Announce Amended Merger Agreement

April 21, 2025 | globenewswire.com

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

April 16, 2025 | businesswire.com

Alumis Inc.; ACELYRIN, INC.: Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

April 5, 2025 | finanznachrichten.de

Alumis Inc. and ACELYRIN, INC. File Joint Definitive Proxy Statement for Proposed Merger

April 5, 2025 | finanznachrichten.de

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLD

March 30, 2025 | morningstar.com

Insider Selling: Acelyrin, Inc. (NASDAQ:SLRN) Insider Sells 3,913 Shares of Stock

March 20, 2025 | insidertrades.com

Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now

March 18, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS, CNTA, SLRN, and BMEA Company Descriptions

Biomea Fusion NASDAQ:BMEA

$1.44 -0.05 (-3.36%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.47 +0.03 (+2.08%)

As of 05/30/2025 06:48 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Centessa Pharmaceuticals NASDAQ:CNTA

$13.14 +0.07 (+0.54%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$13.48 +0.33 (+2.55%)

As of 05/30/2025 05:51 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Pharvaris NASDAQ:PHVS

$16.53 -0.19 (-1.14%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$16.52 -0.01 (-0.03%)

As of 05/30/2025 07:33 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Acelyrin NASDAQ:SLRN

$2.27 0.00 (0.00%)

As of 05/21/2025

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time